Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled

Exclusion Criteria

• •Diagnosis of pneumonia, pneumothorax, pneumomediastinum, COPD, pulmonary tuberculosis, deficiency α1anti antitrypsin, lung mycosis (blastomycosis, histoplasmosis), bronchiectasis, pulmonary cystic fibrosis or other significant respiratory disease, according to the investigator;
• •Pneumothorax history, pulmonary tuberculosis, lung mycosis (blastomycosis, histoplasmosis) and COPD;
• •Immunosuppressive therapy;
• •Survey participants with immunosuppression of any kind;
• •Thoracic surgery history or any prior neoplastic process of the lung;
• •Significant heart disease;
• •Four or more systemic corticosteroid courses in the last 12 months;
• •Participants who have needed hospitalization or care in the emergency room or emergency service (duration\> 12 hours) to airway obstruction control (for exacerbation of asthma), at least once within the last three (03) months;
• •History of asthma crisis with risk of death;
• •Ventilatory support needs due to respiratory failure secondary to asthma within the past five (05) years;
• •Infection of the upper respiratory tract or lower (viral or bacterial) within the last four (04) weeks prior to study entry;
• •Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the medical researcher as a risk to the research participant in the clinical study;
• •Known hypersensitivity to drug components used during the study;
• •Use of forbidden drugs in the clinical study described in Protocol;
• •Smokers and former smokers;
• •HIV infection, whether on antiretroviral treatment;
• •History of abuse of illicit drugs;
• •Disorders diagnosis of hypothalamic-pituitary-adrenal axis (hypocortisolism or hypercortisolism);
• •Presence of severe obstruction of lung airflow that may present a risk of death;
• •Women in reproductive age who do not agree to use hormonal or barrier methods of contraception; except the participants declared that they perform sexual practices or exercise them not to reproductive form;
• •Female participants in a period of pregnancy or breastfeeding;
• •Clinical trial protocols of participation in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
• •Family relationship to the second degree or bond with employees or employees of Sponsor and Research Center.